索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的Meta分析  

Meta-analysis on solifenacin combined with tamsulosin in treatment of type Ⅲ prostatitis

作　　者：陈福兵 张文森[1] 陈正军[1] 杨勇[1] 王和西 蒋诗坤 CHEN Fubing, ZHANG Wensen, CHEN Zhengjun, YANG Yong, WANG Hexi, JIANG Shikun(Department of Urology, Suining First People＇s Hospital, Suining 629000, Chin)

机构地区：[1]遂宁市第一人民医院泌尿外科,四川遂宁637000

出　　处：《药物评价研究》2018年第1期134-139,共6页Drug Evaluation Research

摘　　要：目的系统评价索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的临床疗效。方法计算机检索Pub Med、EMbase、Cochrane Library、中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、中文科技期刊全文数据库(VIP)和万方数据库,收集索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的随机对照试验(RCT),检索时限2000年1月-2017年6月。采用Cochrane协作网推荐的Rev Man 5.3软件对各效应指标进行Meta分析。结果共纳入9项RCTs,计938例Ⅲ型前列腺炎患者。Meta分析结果显示,联合用药组痊愈率[OR=1.82,95%CI(1.30,2.56),P=0.000 5]与总有效率[OR=4.46,95%CI(2.86,6.95),P<0.001]均显著高于对照组,差异有统计学意义(P<0.05);联合用药组NIH-CPSI评分、疼痛症状评分、排尿症状评分、生活质量评分均显著低于对照组,差异有统计学意义(P<0.05)。结论索利那新联合坦索罗辛治疗Ⅲ型前列腺炎较单用坦索罗辛的临床效果好。受纳入文献的质量和样本量限制,上述结论尚待更多大样本、高质量的研究予以进一步证实。Objective To evaluate the efficacy of solifenacin combined with tamsulosin in the treatment of type Ⅲ prostatitis. Methods The randomized controlled trials（RCT） of solifenacin combined with tamsulosin in the treatment of type Ⅲ prostatitis were searched from Pub Med, EMbase, Cochrane Library, CBM, CNKI, VIP database, and Wangfang detabase. Data were collected from January 2000 to June 2017 and also retrieved manually. At the same time, Meta analysis was carried out by using Rev Man 5.3 software. Results A total of nine RCTs were included, including 938 patients with type Ⅲ prostatitis. Meta analysis results showed that the cure rate [OR = 1.82, 95%CI（1.30, 2.56）, P = 0.000 5] and effective rate [OR = 4.46, 95%CI（2.86, 6.95）, P〈0.001] of treatment group were significantly higher than those in control group. Moreover, NIH-CPSI score, symptom of pain score, voiding symptom score and life quality score of treatment group were significantly lower than those in the control group（P〈0.05）. Conclusion Solifenacin combined with tamsulosin in the treatment of type Ⅲ prostatitis has better effect than tamsulosin monotherapy. However, there is limit of methodological quality and sample size, so more RCTs with high quality, large sample, and long-term follow up are required for further verification.

关 键 词：索利那新 坦索罗辛 Ⅲ型前列腺炎 联合用药 META分析 

分 类 号：R978.1[医药卫生—药品]